Literature DB >> 8137261

Aberration of genomic DNA in association with human hepatocellular carcinomas detected by 2-dimensional gel analysis.

H Nagai1, M Ponglikitmongkol, E Mita, Y Ohmachi, H Yoshikawa, R Saeki, Y Yumoto, T Nakanishi, K Matsubara.   

Abstract

Alterations of genomic DNAs in primary hepatocellular carcinomas (HCCs) were examined by restriction landmark genomic scanning (I. Hatada et al., Proc. Natl. Acad. Sci. USA, 88: 9523-9527, 1991) which is a 2-dimensional gel analysis that allows detection of deletion, amplification, or other rearrangements of genomic DNA. Sixteen HCC samples together with their normal counterparts were tested in this manner. Each HCC sample was micromanipulated to minimize possible carryover from non-malignant cells. DNAs from HCCs and their normal counterparts were cleaved with the restriction enzyme NotI, end labeled with 32P, and size fractionated by 2-dimensional electrophoresis using HinfI as the second cleavage enzyme. The resulting spots (about 2000) in HCC samples were compared with their normal counterparts. Five spots were more intense in 10-14 of the 16 HCCs (63-88%). The intensity of several spots was reduced to about half, suggesting the loss of one of two alleles. Some of these decreases were observed frequently in different HCC samples, whereas others were sporadic. Sixty of these spots reproducibly decreased in > 2 cases, with 27 showing a decrease in > 50% of the informative cases. The highest incidence was observed in 14 of 16 samples (88%). No significant correlations were observed between these changes in spots and hepatitis B virus or hepatitis B virus infection. The use of landmarks that show a reproducible increase or decrease in intensity is discussed in conjunction with future studies of genomic alterations inherent in HCC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137261

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Genomic alterations in human glioma cell lines detected by restriction landmark genomic scanning.

Authors:  M Nakamura; N Konishi; S Tsunoda; Y Hiasa; T Tsuzuki; K Takemura; K Kobitsu; T Sakaki
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

2.  Restriction landmark cDNA scanning (RLCS): a novel cDNA display system using two-dimensional gel electrophoresis.

Authors:  H Suzuki; T Yaoi; J Kawai; A Hara; G Kuwajima; S Wantanabe
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

3.  Studies of the inheritance of human ribosomal DNA variants detected in two-dimensional separations of genomic restriction fragments.

Authors:  R Kuick; J Asakawa; J V Neel; M Kodaira; C Satoh; D Thoraval; I L Gonzalez; S M Hanash
Journal:  Genetics       Date:  1996-09       Impact factor: 4.562

4.  Different patterns of DNA alterations detected by restriction landmark genomic scanning in heterogeneous prostate carcinomas.

Authors:  N Konishi; Y Hiasa; M Nakamura; Y Kitahori; K Matsubara; H Nagai
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

5.  Analyses of human gliomas by restriction landmark genomic scanning.

Authors:  M Nakamura; N Konishi; S Tsunoda; Y Hiasa; T Tsuzuki; H Aoki; K Kobitsu; H Nagai; T Sakaki
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

6.  WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer.

Authors:  Hirohide Yoshikawa; Kenichi Matsubara; Xiaoling Zhou; Shu Okamura; Takahiko Kubo; Yaeko Murase; Yuko Shikauchi; Manel Esteller; James G Herman; Xin Wei Wang; Curtis C Harris
Journal:  Mol Biol Cell       Date:  2007-08-29       Impact factor: 4.138

7.  Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma.

Authors:  Kentaro Maemura; Hirohide Yoshikawa; Kazutake Yokoyama; Teruo Ueno; Hitomi Kurose; Kazuhisa Uchiyama; Yoshinori Otsuki
Journal:  Int J Oncol       Date:  2013-01-17       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.